Want to see JP:2413 full AI Analyst Report?
2413 Stock Chart & Stats
¥1834.00
¥16.00(0.84%)
At close: 4:00 PM EDT
¥1834.00
¥16.00(0.84%)
Day’s Range― - ―
52-Week Range¥1,297.00 - ¥2,746.00
Previous CloseN/A
Volume3.52M
Average Volume (3M)2.81M
Market Cap
¥1.29T
Enterprise Value¥1.12T
Total Cash (Recent Filing)¥162.17B
Total Debt (Recent Filing)¥37.56B
Price to Earnings (P/E)27.9
Beta0.55
Next Earnings
Nov 04, 2026EPS Estimate
18.99Next Dividend Ex-DateN/A
Dividend Yield1.15%
Share Statistics
EPS (TTM)68.68
Shares Outstanding679,128,200
10 Day Avg. Volume3,101,330
30 Day Avg. Volume2,810,546
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)2.66
Price to Sales (P/S)3.09
P/FCF Ratio17.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,010.00Price Target Upside9.60% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)77.03
Revenue Forecast (FY)¥388.18B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage gives M3 substantial financial flexibility and reduces the pressure of interest costs or refinancing needs. Growing equity and healthy returns on equity also support continued investment in its healthcare platforms while improving resilience through changing business conditions.
Strong Free Cash FlowFree cash flow that closely tracks earnings indicates strong earnings quality and provides internally generated funds for product development, platform investment, acquisitions, or shareholder returns. This cash-generation profile strengthens M3’s ability to compound its healthcare information ecosystem.
Re-accelerating Growth And Profitable ModelThe return to double-digit revenue growth while maintaining high gross and net margins suggests durable demand for M3’s healthcare information and digital services. Strong profitability gives the company capacity to reinvest in its professional network and support future expansion.
Bears Say
Margin CompressionAlthough profitability remains strong, the multi-year margin decline indicates that higher costs or a less favorable business mix is reducing operating leverage. If this persists, M3 may convert future revenue growth into earnings less efficiently and face pressure on long-term profit expansion.
Uneven Operating Cash ConversionOperating cash flow has not consistently matched reported earnings, implying working-capital or timing effects are absorbing part of the accounting profit. Persistent conversion weakness could reduce the cash available for reinvestment and make reported earnings less representative of near-term funding capacity.
Earnings Below Prior PeakThe recovery in net income has not yet restored the company’s earlier earnings high, showing that revenue growth has not fully translated into peak profitability. This limits evidence of a complete earnings-power recovery and leaves results more exposed to continued cost or mix pressure.
M3 News
2413 FAQ
What was M3 Inc’s price range in the past 12 months?
M3 Inc lowest stock price was ¥1297.00 and its highest was ¥2746.00 in the past 12 months.
What is M3 Inc’s market cap?
M3 Inc’s market cap is ¥1.29T.
When is M3 Inc’s upcoming earnings report date?
M3 Inc’s upcoming earnings report date is Nov 04, 2026 which is in 13 days.
How were M3 Inc’s earnings last quarter?
M3 Inc released its earnings results on Aug 06, 2026. The company reported ¥13.6 earnings per share for the quarter, missing the consensus estimate of ¥20.087 by -¥6.487.
Is M3 Inc overvalued?
According to Wall Street analysts M3 Inc’s price is currently Undervalued.
Does M3 Inc pay dividends?
M3 Inc pays a Annually dividend of ¥22 which represents an annual dividend yield of 1.15%. See more information on M3 Inc dividends here
What is M3 Inc’s EPS estimate?
M3 Inc’s EPS estimate is 18.99.
How many shares outstanding does M3 Inc have?
M3 Inc has 679,128,200 shares outstanding.
What happened to M3 Inc’s price movement after its last earnings report?
M3 Inc reported an EPS of ¥13.6 in its last earnings report, missing expectations of ¥20.087. Following the earnings report the stock price went up 6.11%.
Which hedge fund is a major shareholder of M3 Inc?
Currently, no hedge funds are holding shares in JP:2413
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
M3 Inc
M3, Inc. is a Japanese company that delivers a broad spectrum of internet-based services, predominantly catering to medical professionals and the broader healthcare industry. Its operations are segmented into five key areas: Medical Platform, Evidence Solution, Career Solution, Site Solution, and Overseas. M3 manages several specialized online platforms, including m3.com, an exclusive information portal for healthcare professionals; MR-kun, which ensures member doctors receive ongoing updates via the m3com platform; QOL-kun, offering non-medical life support; and AskDoctors, where certified physicians address public health inquiries from the general public. Internationally, it operates MDLinx for U.S. medical professionals and Doctorsnetuk, a U.K.-based site supporting pharmaceutical companies and providing drug information databases across France, Germany, and Spain. Furthermore, M3 offers dedicated career services for doctors and pharmacists through its m3com CAREER platform. Its diverse business portfolio extends to sales and marketing for pharmaceutical and medical device companies, as well as the development, sale, and maintenance of electronic medical records and equipment for healthcare facilities. M3 also conducts surveys for medical professionals, offers online sales and marketing assistance to pharmaceutical firms, provides management consulting to medical institutions, delivers home-visit nursing services, and specializes in human resource solutions for healthcare staff, alongside managing clinical trial facilities. Established in 2000, the company was initially named So-netM3, Inc., before rebranding to M3, Inc. in January 2010. Its headquarters are located in Tokyo, Japan.
2413 Stock 12 Month Forecast
Average Price Target
¥2,010.00
▲(9.60% Upside)